This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Karo Pharma Dividends and Buybacks

Dividend criteria checks 0/6

Key information

0%

Dividend yield

-15.0%

Buyback Yield

Total Shareholder Yield-15.0%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ratio0%

Recent dividend and buyback updates

No updates

Recent updates

Karo Pharma (STO:KARO) Has No Shortage Of Debt

Oct 14
Karo Pharma (STO:KARO) Has No Shortage Of Debt

Is Karo Pharma (STO:KARO) A Risky Investment?

Jul 10
Is Karo Pharma (STO:KARO) A Risky Investment?

Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Mar 23
Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Feb 24
Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Feb 22
Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

Feb 01
Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if KARO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KARO's dividend payments have been increasing.


Dividend Yield vs Market

Karo Pharma Dividend Yield vs Market
How does KARO dividend yield compare to the market?
SegmentDividend Yield
Company (KARO)0%
Market Bottom 25% (SE)1.6%
Market Top 25% (SE)4.9%
Industry Average (Pharmaceuticals)2.7%
Analyst forecast (KARO) (up to 3 years)n/a

Notable Dividend: Unable to evaluate KARO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KARO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: KARO is not paying a notable dividend for the Swedish market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as KARO has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/25 08:12
End of Day Share Price 2022/11/24 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Karo Pharma AB (publ) is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander LindströmABG Sundal Collier
Camilla OxhamreCarnegie Investment Bank AB
Mats LissKepler Cheuvreux